mp3 dönüştür

We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

AML treatment combo helps most trial patients reach remission

Treatment with the targeted therapy Venclexta (venetoclax) in combination with chemotherapy led to disease remission for most people with hard-to-treat acute myeloid leukemia (AML) in an early clinical trial, with most patients able to undergo stem cell transplant...

Source: Pharmacy Times articles Post Content Read More

Experimental therapy outperforms approved treatment in PNET trial

The experimental therapy 177Lu-edotreotide outperformed the approved treatment everolimus in prolonging progression-free survival in people with pancreatic neuroendocrine tumors (PNETs), according to a new analysis of a Phase 3 clinical trial. ITM Isotope Technologies...

Source: Pharmacy Times articles Post Content Read More

New targeted therapy for childhood brain cancer nears European approval

A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of pediatric low-grade glioma (pLGG). If authorized by the European Commission, the therapy would become a new targeted option for children 6...

New trial data show alnodesertib may slow ovarian cancer progression

A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant high-grade serous ovarian carcinoma (HGSOC) in an early clinical trial. Findings from the Phase 2a study...
Latest Data

Latest Publications

The [(18)F]FDG PET/CT for prognostic stratification in multiple myeloma: A systematic review and meta-analysis

Eur J Nucl Med Mol Imaging. 2026 Mar 7. doi: 10.1007/s00259-026-07830-5. Online ahead of print. NO...

Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis

Front Pharmacol. 2026 Feb 12;16:1687718. doi: 10.3389/fphar.2025.1687718. eCollection 2025....

Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis

Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02880-y. Online ahead of print. NO ABSTRACT...

The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis

Cardiooncology. 2026 Feb 10. doi: 10.1186/s40959-025-00435-1. Online ahead of print. NO ABSTRACT...

Email

info@myeloma360.com

bahisliongalabet1xbet